2024
Rethinking Our Roots: The Ground-Up Approach to Heart Health & Planetary Sustainability
Saad A, Brandt E, Faridi K, Paster J, Sheth S, Freeman A, Ramirez V, Aggarwal M. Rethinking Our Roots: The Ground-Up Approach to Heart Health & Planetary Sustainability. The American Journal Of Medicine 2024 PMID: 39383927, DOI: 10.1016/j.amjmed.2024.09.028.Peer-Reviewed Original ResearchPlanetary healthCardiovascular diseasePromote planetary healthPoor dietary habitsModifiable risk factorsNutrition educationChronic illnessDietary habitsFood insecurityRisk factorsHealthPlant-forward dietsTreat cardiovascular diseasesUnited StatesFood systemsAgricultural practicesDiseasePracticeComplex issuesIllnessNutritionHabitsEducationProposed Mechanisms and Associations of COVID-19 with Cardiometabolic Risk Factors.
Reddy K, Faridi K, Aggarwal M, Tirumalai A, Singh T, Tejtel K, Williams K, Litwin S, Dastmalchi L, White B, Barnard N, Ornish D, Batts T, Ajene G, Aspry K, Kris Etherton P, Hull S, Freeman A. Proposed Mechanisms and Associations of COVID-19 with Cardiometabolic Risk Factors. American Journal Of Lifestyle Medicine 2024, 15598276241269532. PMID: 39540176, PMCID: PMC11556543, DOI: 10.1177/15598276241269532.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCardiometabolic riskLifestyle choicesCardiovascular diseaseHealthy lifestyle choicesCardiometabolic risk factorsHealth promotionReduce disease burdenCode BlueCardiovascular healthDisease preventionCOVID-19 morbidityPoor nutritionDisease burdenCOVID-19Disease burden resultsPublic healthGlobal leading causeLeading causeRisk factorsAssociation of COVID-19HealthLifestyleBurden resultsNutritionCardiovascular medicinePragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial
Shah N, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, Riello Iii R, Faridi K, Ahmad T, Wilson F, Desai N. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010335. PMID: 38634282, DOI: 10.1161/circoutcomes.123.010335.Peer-Reviewed Original ResearchElectronic health recordsElectronic health record alertsHigh-risk atherosclerotic cardiovascular diseaseLipid lowering therapyAtherosclerotic cardiovascular diseasePragmatic trialCardiovascular diseaseProportion of patientsYale New Haven HealthLDL-CSecondary outcomesPrimary outcomeInternal medicine cliniciansEHR alertUsual careHealth recordsProvider levelCluster-randomizedLDL-C managementLDL-C levelsAdverse cardiovascular eventsRandomized clinical trialsTreatment of hyperlipidemiaCliniciansCardiovascular events
2023
Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
Faridi K, Desai N. Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease. American Journal Of Preventive Cardiology 2023, 14: 100491. PMID: 36969953, PMCID: PMC10036885, DOI: 10.1016/j.ajpc.2023.100491.Commentaries, Editorials and Letters
2022
Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients
2021
Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2019
Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids
Faridi KF, Quispe R, Martin SS, Hendrani AD, Joshi PH, Brinton EA, Cruz DE, Banach M, Toth PP, Kulkarni K, Jones SR. Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. Journal Of Clinical Lipidology 2019, 13: 634-644. PMID: 31320236, DOI: 10.1016/j.jacl.2019.06.001.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein cholesterolRemnant lipoprotein cholesterolLipoprotein cholesterolLipid parametersVertical auto profile ultracentrifugationRLP-C levelsAtherosclerotic cardiovascular diseaseLipid panelMedian ageHighest quintileRisk factorsCardiovascular diseaseSecond quintileFriedewald equationCholesterolQuintileDlRLPParameters correlatesSubject differencesLipidsCohortDisease
2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claimsVitamin D deficiency and non-lipid biomarkers of cardiovascular risk
Faridi KF, Lupton JR, Martin SS, Banach M, Quispe R, Kulkarni K, Jones SR, Michos ED. Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk. Archives Of Medical Science 2017, 13: 732-737. PMID: 28721139, PMCID: PMC5510501, DOI: 10.5114/aoms.2017.68237.Peer-Reviewed Original ResearchCardiovascular riskOdds ratioCardiovascular diseaseHigh-sensitivity C-reactive proteinUric acidElevated levelsMultivariable-adjusted modelsVitamin D deficiencyC-reactive proteinClinical laboratory databaseCross-sectional analysisUnited States populationD deficiencyDeficient womenHs-CRPSD ageElevated biomarkersVitamin DD levelsLaboratory databaseLogistic regressionΓ-glutamyltransferaseCreatinineBiomarkersWomenSerum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study
Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition 2017, 38: 85-93. PMID: 28526388, PMCID: PMC5443111, DOI: 10.1016/j.nut.2017.01.008.Peer-Reviewed Original ResearchConceptsIncident dyslipidemiaLipid changesLongitudinal community-based studyAdjusted average differencesDemographic-adjusted modelsLipid-lowering therapySerum vitamin DCommunity-based studyBaseline dyslipidemiaLipid trendsIncident useCardiovascular riskClinical characteristicsSD ageVitamin DARIC studyAtherosclerosis RiskCardiovascular diseaseLipid levelsDyslipidemiaCommunity studyRatio of TCHDLMixed effects modelsBaseline